NCT03816436 is a clinical trial of Follow- up (FU) assessment in Clavicular Length, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT03816436?

NCT03816436 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT03816436?

Interventions in NCT03816436: Follow- up (FU) assessment.

What condition does NCT03816436 study?

NCT03816436 studies Clavicular Length.

Is NCT03816436 still recruiting?

NCT03816436 is currently completed. Last updated 24 April 2019.

Last reviewed 2019-04-24 · How we verify

NCT03816436

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Clavicular Length Restoration in the Treatment of Non-unions of Clavicular Midshaft and Lateral Fractures

Completed Last updated 24 April 2019

What this trial tests

trial testing Follow- up (FU) assessment in Clavicular Length in 46 participants. Completed in 25 September 2018.

Timeline

17 August 2018

Primary endpoint
25 September 2018

25 September 2018

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	46
Start date	17 August 2018
Primary completion	25 September 2018
Estimated completion	25 September 2018
Sites	2 locations across Switzerland

Drugs / interventions tested

Follow- up (FU) assessment

Conditions studied

Clavicular Length — all drugs for Clavicular Length →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Clavicular Length. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluating the impact of plate treatment and cortical bone grafting of clavicular midshaft and lateral non- unions on restoration of clavicular length and bony healing and its association with functional outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03816436 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 24 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03816436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing